Dr Mike Lynch OBE FREng FRS
Founder, Invoke Capital
Mike is a celebrated technologist and has a proven track record of identifying and monetising fundamental technologies.
Having pioneered three of the biggest success stories in UK tech – Autonomy, Blinkx and Darktrace – Mike is regarded as Britain's most established technology entrepreneur. Dr Lynch read Natural Sciences at Cambridge University, where he also gained a Ph.D. and held a research fellowship in adaptive pattern recognition. In the late 1980s he founded his first company, Lynett Systems, before founding Autonomy in 1996. Mike served as CEO of Autonomy for 15-years, during which time it became one of the UK's most successful technology companies on the FTSE100. It was acquired by HP for $11 billion in 2011.
In 2012, Mike founded Invoke Capital to create, invest in and support world-leading fundamental technology businesses within Europe. Portfolio companies include the world-leader in cyber AI, Darktrace, which employs more than 1,500 people globally, and Featurespace, the most advanced platform for fraud and financial crime management.
Public service career
Referred to as the UK's answer to Bill Gates, Mike has won numerous awards. He was awarded an OBE for Services to Enterprise in 2006 and was elected to the Prime Minister's Council for Science and Technology in 2011, where he advised on matters including the opportunities and risks of the development of AI in the UK and the Government’s role in the regulation of these technologies.
Mike is a fellow of the Royal Academy of Engineering and an honorary fellow of Christ's College Cambridge. He was elected a Fellow of the Royal Society in April 2014 and a trustee of the National Endowment for Science Technology and the Arts (NESTA) in 2010.
Mike is a generous supporter of many causes, including the Royal Botanic Gardens - Kew, Cancer Research UK, Cambridge University, The Prince's Trust's technology group and a number of educational charities. He also contributes to conservation charities and preserves rare breeds.
Dr Lynch won a scholarship to Bancroft's School, Woodford.
met Peter Rayner, his mentor in the signal processing laboratory of the engineering department.
After graduating, Mike went on to do a PhD in signal processing and connectionist models at Cambridge University and then undertook a research fellowship in adaptive pattern recognition.
In the late 1980s, Dr Lynch founded his first company, Lynett Systems, which produced designs and audio products for the music industry. One invention included an ADAS sampler for Atari, Mac and PC.
Dr Lynch founded Cambridge Neurodynamics, which specialised in computer-based fingerprint recognition. Customers included the South Yorkshire Police Department. Mike sold the company in 2005.
As a spinoff from Cambridge Neurodynamics, Dr Lynch founded Autonomy based on his research into adaptive pattern recognition at Cambridge University.
Mike served as CEO of Autonomy for over 15 years, in which time the company made a series of successful acquisitions including Virage, Verity and Interwoven, and became one of the UK's most successful technology companies on the FTSE100.
Mike was awarded an OBE for Services to Enterprise in the 2006 New Year Honours.
Silicon.com named Mike one of the top five most influential people in technology alongside Steve Jobs and Tim Berners-Lee.
Autonomy was acquired by HP for $11billion.
Mike was elected to the Prime Minister's Council for Science and Technology where he advised on the opportunities and risks of the development of AI in the UK and the Government's role in the regulation of these technologies, amongst other issues.
Mike founded Invoke Capital with the aim of creating, investing in and supporting fundamental technology businesses emerging across Europe.
Invoke Capital founded Cambridge-based start-up, Darktrace, the world-leader in cyber AI that supports over 4,000 organisations globally.
Mike was elected a Fellow of The Royal Society where he advised on subject matters including Industry and Innovation.
Invoke Capital led the Series B investment round in Sophia Genetics, a Swiss genomics business that is now the European leader in data-driven medicine.
Invoke Capital founded Cambridge-based start-up, Luminance, an artificial intelligence platform for lawyers. Luminance is now valued at over $100million and supports more than 300 law firms globally. Mike sits on the Board of Directors for Luminance.
Invoke Capital invested in Featurespace, the leading machine learning company for fraud detection, which was founded by Cambridge University Professor, Bill Fitzgerald.
Invoke Capital launches 'Hearable', a deep learning and AI-driven mobile application for people with hearing loss.
Darktrace reaches valuation of over $2billion.
The Latest From Invoke Insights
The UK's post-Brexit opportunity in tech
With Brexit done, the COVID-19 vaccine being rolled out and the country playing host to the G7 Summit and COP26; 2021 marks the beginning of a new era for the UK. In this blog post, Dr Mike Lynch discusses why this must be an era of technology, science and innovation.
Mike Lynch: "Post-Brexit, we have the freedom to move faster and go further in developing regulatory frameworks that allow fundamental technologies to flourish commercially in the UK. If these are at the heart of the government’s agenda for 2021, I have no doubt the UK will fulfil its goal of becoming a science."
In conversation with Dr Mike Lynch OBE and Matthew Gould, British civil servant and CEO of NHSX.
2020 has been a year that not many people would have anticipated turning out the way it has, and it has put a huge focus on the NHS – both celebrating the staff on the frontline, but also showing its difficulties. And while in the corporate world we have seen an acceleration in the adoption of digital technologies, medicine is also one of the sectors in which emerging technologies are having the most profound effect.
In this podcast, Dr Lynch and Matthew Gould, CEO of NHSX, a joint unit between the Department for Health and Social Care and NHS England, set up to ensure that staff and patients have the technology they need, discuss the impact of the Covid-19 pandemic, the rise of personalised medicine and which technologies are going to have the biggest impact on our health.
Dr Mike Lynch on which emerging technologies in science and tech the UK can capitalise on.
What is really going to change the world in tech? We're now living in a world in which a lot of our day-to-day tasks are being done by technology. In this video, Dr Lynch discusses the impact that advanced technologies such as artificial intelligence and quantum computing are having on peoples' lives, commerce and the economy.
Mike Lynch: "One of the phrases that you can't avoid now if you read the paper is Artificial Intelligence. A lot of what is out there is not very well informed extrapolation. But putting that aside, underneath that there is something absolutely fundamental that is going to change most aspects of our world."
Read more insights here.